Dedicated to Discovery. Committed to Care.

Paths of Progress

Spring/Summer 2006 Paths of Progress

Prostate cancer survivor Norvel Cason, 62, finished his chemotherapy and radiation treatment at Dana-Farber in 2000 and now encourages others to get screened. "When I was diagnosed, I was totally clueless about prostate cancer; I thought it was something other people got," the Attleboro, Mass., software developer says. "I am overjoyed today that I went to Dana-Farber when I did."

Fall/Winter 2006
Volume 15, Number 2

Contents

Features

  • Facing prostate cancer
    By Robert Levy

    In laboratories, clinics, and outreach vans, Dana-Farber faculty and staff are seeking answers to how prostate cancer cells behave, why the disease strikes black men at higher rates, and what can be done to clarify treatment choices.

  • Life as a postdoc
    By Saul Wisnia and Sam Ogden

    A glimpse into the daily routine of postdoctoral fellow Susana Godinho, PhD, on her path to becoming an independent investigator.

  • Silence is golden
    By Richard Saltus

    Dana-Farber investigators are tapping into a new technique called RNA interference to learn about genes’ functions by "silencing" them.

  • Translation, please
    By Debra Ruder

    The prospect of helping patients with rare neuroendocrine tumors has brought together two DFCI scientists using the translational approach promoted by Institute founder Sidney Farber, MD.

  • In the neighborhood
    By Robert Levy

    Dana-Farber investigators are gaining insights into the molecular "conversation" between cancer cells and their surrounding tissue.

  • First Person: John Kerry
    Edited by Debra Ruder

    U.S. Senator John Kerry casts a vote for survivorship as he discusses his experience overcoming prostate cancer and aiding Dana-Farber’s cause.

  • 'I believe we can do better'

    Kimberly Stegmaier, MD reflects on her roles of researcher and clinician at Dana-Farber.

Departments

Credits

President, Dana-Farber Cancer Institute Edward J. Benz Jr., MD
Chief of Staff Stephen E. Sallan, MD
Chief Medical Officer Lawrence N. Shulman, MD
Chief Scientific Officer Barrett J. Rollins, MD
Chief Clinical Officer Philip W. Kantoff, MD
Chair, Medical Oncology James D. Griffin, MD
Chair, Pediatric Oncology Stuart H. Orkin, MD
Chair, Radiation Oncology Jay R. Harris, MD
Chair (Acting), Executive Committee for Research David M. Livingston, MD
Senior VP for Experimental Medicine Lee M. Nadler, MD
Senior VP for Patient Care Services, Chief Nurse Patricia Reid Ponte, RN, DNSc, FAAN

Senior VP for Communications Steven R. Singer
Director of Publications Paul Hennessy
Editor Debra Ruder
Design/Production John DiGianni
Associate Editor Robert Levy
Articles Editor Saul Wisnia
Staff Writers Christine Cleary, Richard Saltus, Dawn Stapleton
Production Assistance Christine Benedix, Patricia Cleary, Kathleen Raven
Photography Sam Ogden, Gretje Ferguson (p. 19), John Deputy (p. 30), Getty Images (p.31)

Paths of Progress is published twice a year by Dana-Farber Cancer Institute's Department of Communications. If you have any comments or would like to be removed from the mailing list, contact:

Debra Ruder
Editor, Paths of Progress
Dana-Farber Cancer Institute, Department of Communications
44 Binney Street
Boston, MA 02115

(617) 632-4090
debra_ruder@dfci.harvard.edu

Copyright © 2006 Dana-Farber Cancer Institute. All rights reserved.

Paths of Progress Archive

E-mail this page

History of advances

From achieving the first remissions of ALL and Wilm's tumor in pediatric patients in the '40s and '50s, to the development of Gleevec, the first "smart" cancer drug, in the late '90s, Dana-Farber researchers and clinicians have been at the forefront of discovery in cancer care and research. learn more